anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, endocrinology. SUBSTANCE: invention relates to treatment of diabetes mellitus and diabetes-associated complications. Invention proposes to administrate preparation among the group involving enhancers for sensitivity to insulin but excluding troglitazone in combination with preparation taken among the group of involving enhancers of insulin secretion and taken also among inhibitors of alpha-glycosidase, inhibitors of alpha-reductase, biguanides, statin compounds, inhibitors of squalene, fibrate compounds, enhancers of LDL (low density lipoproteins) catabolism and inhibitors of ACF (augiotensinconversional ferment). Combinations of these preparations are administrated as a mixture also. Indicated combinations, except for hypoglycemic effect, provide reducing weight, blood plasma triglycerides level, unexpectedly high activity with respect to reducing blood glucose level being in retention of dose of insulin sensitivity enhancer. EFFECT: enhanced and valuable properties of enhancers. 12 cl, 5 tbl
Close to 2.5 million Americans are currently living with post-stroke aphasia, a debilitating communication disorder affecting multiple language modalities. Most stroke survivors with aphasia have acquired reading deficits, which persist chronically and severely limit life participation and autonomy. There is an urgent need for effective treatments grounded in stroke neurobiology which yield robust functional improvements. This project is a randomized controlled trial, which will recruit 70 individuals with chronic left-hemisphere stroke. Participants will complete 40 sessions of targeted reading treatment combined with either 20 minutes of moderate aerobic exercise or light stretching. Participants will undergo 3 Magnetic Resonance Imaging (MRI) scans, administered before the intervention, after the initial exercise session, and after the full course of treatment. They will also complete behavioral testing before and after the intervention. The outcome of this study has the potential to radically change how reading treatments are applied, increasing their effectiveness, and ultimately improving the lives of 2.5 million Americans living with stroke-related aphasia. In addition, it is likely that the results will contribute to the understanding of stroke recovery mechanisms thereby fundamentally advancing the field of neurorehabilitation.
There is disclosed block and graft copoly-mers which, in one embodiment, contain both a temperature-sensitive polymer component and a pH-sensitive polymer component, and the use of such copolymers for topical drug delivery to a treat-ment area. The block and graft copolymers may be physically mixed with one or more drugs to form a copolymer-drug mixture. This mixture may be applied to the treatment as solid particles sus-pended in a pharmaceutically acceptable carrier, or as a liquid which gels upon contact with the treat-ment area. Upon contact with the treatment area, the pH-sensitive polymer component hydrates and swells, thereby causing release of the drug from the mixture. In addition, such hydration and swelling causes the pH-sensitive polymer component to ad-here to the tissue of the treatment area, thus prolong-ing contact time. The temperature-sensitive poly-mer component resists hydration and swelling of the mixture, thereby imparting a sustained and con-trolled release of the drug to the treatment area. In another embodiment of this invention, bloc and graft copolymers, and hydrogels thereof, are disclosed having broad industrial applicability.
Stimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
The invention provides a kind of extracting method of selenium worm grass essence.It is characterized in that by following extraction step：A. selenium worm grass drying process；B. crush；C. refluxing extraction；D. it is spray-dried；E. it is vacuum-packed.A kind of extracting method of selenium worm grass essence of the present invention uses the step water bath reflux method of solvent auxiliary ultrasonic two, makes extracts active ingredients in selenium worm grass more abundant, and the recovery rate of selenium reaches more than 90%；The step water bath reflux method of solvent auxiliary ultrasonic two greatly shortens more than 2/3 by optimizing extraction time, extraction time compared with conventional method；Extracting temperature has protective effect, while greatling save energy consumption below 60 DEG C to active ingredient in case of thermal instability, facile hydrolysis or the medicinal material of oxidation.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to mitoxantrone stable solution. Stable solution contains mitoxantrone hydrochloride solution and 0.001-0.15% of sodium EDTA as a stabilizing agent. Invention provides preparing the sulfite-free injection solution and excludes byside effects in parenteral route of administration. EFFECT: improved properties of solution. 7 cl, 1 tbl
INTRODUCTION: Weight bias toward individuals with higher body weights is present in health care settings. However, there has been limited quantitative exploration into weight bias among perinatal care providers and its potential variations based on demographic characteristics. The aim of this study was to examine if the direction and extent of weight bias among midwives certified by the American Midwifery Certification Board (AMCB) varied across age, years since certification, body mass index (BMI), race, ethnicity, and US geographic region.
METHODS: Through direct email listservs, postcard distribution, social media accounts, and professional networks, midwives were invited to complete an online survey of their implicit weight bias (using the Implicit Association Test) and their explicit weight bias using the Anti-Fat Attitudes Questionnaire (AFA), Fat Phobia Scale (FPS), and Preference for Thin People (PTP) measure.
RESULTS: A total of 2106 midwives who identified as Black or White and resided in one of 4 US geographic regions participated in the survey. Midwives with a lower BMI expressed higher levels of implicit (P <.01) and explicit (P ≤.01) weight bias across all 4 measures except for the AFA Fear of Fat Subscale. Implicit weight bias levels also varied by age (P <.001) and years since certification (P <.001), with lower levels among younger midwives (vs older) and those with fewer years (vs more) since certification. Only age and BMI remained significant (P <.001) after adjusting for other demographic characteristics. Lower explicit weight bias levels were found among midwives who identified as Black (vs White) on 2 measures (FPS: adjusted β = -0.07, P = .004; PTP: P = .01).
DISCUSSION: This was the first quantitative study of how weight bias varies across demographic characteristics among a national sample of midwives. Further exploration is needed in more diverse samples. In addition, research to determine whether weight bias influences clinical decision-making and quality of care is warranted.
BACKGROUND: Ischemic stroke is one of the leading causes of chronic disability worldwide, and stroke-induced heart damage can lead to death. According to research, patients with a variety of brain disease have good clinical results after vagus nerve stimulation (VNS). After ischemic stroke, mast cells (MCs) degranulate and release a large number of mediators, which may cause systemic inflammation. Chymase secreted by MCs can increase the levels of pathological angiotensin II (AngⅡ), which plays a crucial role in the deterioration of heart disease. Our goal was to develop a minimally invasive, targeted, and convenient VNS approach to assess the impact of VNS and to clarify the relationship between VNS and MCs in the prognosis of patients with myocardial atrophy after acute ischemic stroke.
METHODS: In this study, we verified the role of VNS in the treatment of myocardial atrophy after stroke and its molecular mechanism using a rat model of middle cerebral artery occlusion (MCAO/r). Behavioral studies were assessed using neurobehavioral deficit scores. Enzyme-linked immunosorbent assays, immunofluorescence staining, Western blotting and qRT-PCR were used to analyze the expression levels of myocardial atrophy, MC and inflammatory markers in rat hearts.
RESULTS: VNS improved myocardial atrophy in MCAO/r rats, inhibited MC activation, reduced the expression of chymase and AngⅡ, and inhibited the expression of proinflammatory factors. The chymase activator C48/80 reversed these effects of VNS. Chymase activation inhibited the effect of VNS on myocardial atrophy in MCAO/r rats, increased AngⅡ expression and aggravated inflammation and autophagy. The myocardial atrophy of MCAO/r rats was improved after chymase inhibition, and AngⅡ expression, inflammation and autophagy were reduced. Our results suggest that VNS may reduce the expression of chymase and AngⅡ by inhibiting MC activation, thereby improving myocardial atrophy and reducing inflammation and autophagy in MCAO/r rats. Inhibition of MC activation may be an effective strategy for treating myocardial atrophy after stroke.
CONCLUSIONS: VNS inhibits MC activation and reduces the expression of chymase and AngII, thereby alleviating myocardial atrophy, inflammation and autophagy after stroke.
OBJECTIVE: The UK NHS Getting It Right First Time report (2021) recommended that a significant proportion of native tissue vaginal prolapse operations should be undertaken as day-case procedures (target: 80% anterior compartment, 70% posterior compartment, 60% combined anterior/posterior compartment). The evidence for perioperative care, options for anaesthesia and outcomes of day-case vaginal prolapse surgery is limited. This study aimed to establish current practice amongst UK gynaecologists and explore perceived barriers to implementing day-case surgery for pelvic organ prolapse. Study design A pre-tested 16-item survey was emailed to British Society of Urogynaecology members in July 2022. This survey recorded rates of day-case prolapse surgeries, barriers to implementation and practices for managing urethral catheters, vaginal packs, intraoperative anaesthetics and perioperative care. Responses to free-text questions were independently analysed by two of the authors and underwent thematic analysis.
RESULTS: 121 eligible responses were received (28 % response-rate): 41 % never undertook day-case prolapse repair, 16 % undertook < 5 per year and 26 % undertook > 20 cases per year. There was no significant difference in training level or hospital setting between those groups. Reasons cited for not undertaking day-case prolapse surgery included concerns about vaginal packs and urinary catheters (92 %) postoperative complications (67 %), early discharge of elderly patients (60 %) and a lack of published evidence (39 %) or national guidance (35 %). For those currently undertaking day-case prolapse surgery; 67 % used general anaesthesia, 15 % spinal with short-acting local anaesthetic, 14 % spinal with long-acting local anaesthetic and 3 % local anaesthetic alone. Vaginal packs and self-retaining urethral catheters were used by 68 % and 70 % respectively. Concerns regarding the management of vaginal packs and urinary catheters were the most frequently cited barrier to implementing day-case surgery for pelvic organ prolapse amongst free-text responses. There were wide variations in managing catheters and packs, and in managing readmissions.
CONCLUSIONS: There is significant variation in uptake and practice for day-case prolapse surgery in the UK, with legitimate clinical concerns a barrier to its implementation. Further evaluation and development of robust, evidence-based management pathways are required to make day-case prolapse surgery consistent, feasible and defensible in clinical practice.
Methods and systems for purifying one or more microbial cells and/or viruses from a biological sample are provided. The biological sample is added to a well disposed in a medium. A potential is applied across the medium to cause the contaminants to enter one or more walls of the well, and retain the microbial cells and/or viruses in the well. The microbial cells and/or viruses can be removed from the well, and optionally adhered or fixed to a surface, or detected. In one embodiment, the microbial cells and/or viruses are retained in the well by embedding in the medium. The medium including the embedded microbial cells and/or viruses may be excised or otherwise removed and transferred to a glass slide or other solid surface. In some examples, a biological sample containing contaminants and one or more microbial cells is introduced to a well disposed in a porous filter medium, wherein the porous filter medium includes pores smaller than the one or more microbial cells, thereby preventing the one or more microbial cells from entering the porous filter medium.
Background: Robotic adrenalectomy has become a surgical treatment option for benign and selected malignant adrenal diseases. We aimed to evaluate the eligibility of two-port robotic posterior retroperitoneoscopic adrenalectomy (PRA) as an alternative to the conventional three-port technique by comparing their surgical outcomes. Materials and Methods: This retrospective cohort study compared the clinicopathological factors and surgical outcomes among 197 patients who underwent two-port or three-port robotic adrenalectomy between 2016 and 2020 in a single tertiary center. For further evaluation, propensity score matching was performed to reduce the selection bias in population characteristics. Results: Patients were categorized by the number of ports (two-port group, 87; and three-port group, 110). The two-port group compared with the three-port group was significantly older (P = .006) and had a smaller mean tumor size (P = .003) and shorter mean operation time (P = .001). Upon comparing clinicopathologic characteristics according to adrenal disorders, for pheochromocytoma, the three-port group had a larger tumor size and a longer operation time. For Cushing's syndrome, the operation time was short and numeric rating scale pain score was significantly low in the two-port group. After propensity score matching, the two-port group had a short operation time and a significantly low postoperative pain score (P < .05). Predictive factors associated with prolonged operation time included male gender, an increased number of ports, and large tumor size. Conclusions: The two-port technique resulted in a shorter operation time and lower pain score compared with the three-port technique. The two-port technique may be a safe alternative to the conventional three-port technique for robotic PRA.
Protocol 1: mental math and handgrip exercise. Protocol 2: systemic stressors and end-organ receptor stimulation. Protocol 3: local heating.
PURPOSE:To obtain a well-balanced fragrant resin composition capable of containing various perfumes in large quantities and excellent in persistence of a fragrance by mixing a perfume, a saturated hydrocarbon, and an ethylene/ vinyl acetate copolymer. CONSTITUTION:The title resin composition consists of 40-95wt.% ethylene/vinyl acetate copolymer and 50-60wt.% mixture of 50-90wt.% perfume with 10-50wt.% saturated hydrocarbon. The saturated hydrocarbon may be a paraffin or isoparaffin having an initial boiling point of 150 deg.C or higher and a final boiling point of 300 deg.C or lower. The saturated hydrocarbon of a boiling point below said lower limit is undesirable because of dangerousness due to low flash point, while that of a boiling point said upper limit is undesirable because of difficulty in infiltrating a perfume therein due to high viscosity. The ethylene/vinyl acetate copolymer is a copolymer containing 5-35wt.% vinyl acetate. The vinyl acetate content below said lower limit causes difficulty in infiltration of a perfume, while that above the upper limit causes limit causes softening of the copolymer when impregnated with a perfume, both of which are undesirable.
Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells, both in vitro and in vivo. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, Y/CPQGNH maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) is effective in reversing both nephrotoxic and ischemic acute renal failure in rats. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.
Cystic Fibrosis (CF) is a complex disorder that requires multidisciplinary expertise for effective management. The GALAXY study estimated the prevalence of constipation to be about 25% among People with Cystic Fibrosis (PwCF), identifying it as one of the common gastrointestinal (GI) symptoms within this patient population. Quality of Life (QoL) assessments uncovered high patient dissatisfaction, highlighting the imperative need for enhanced treatment strategies. Similarly, Distal Intestinal Obstruction Syndrome (DIOS) is a unique condition exclusive to PwCF that, if left undiagnosed, can lead to considerable morbidity and mortality. Given the broad spectrum of differential diagnoses for abdominal pain, including constipation and DIOS, it is paramount for healthcare providers to possess a clear understanding of these conditions. This paper aims to delineate various differentials for abdominal pain while elucidating the pathogenesis, diagnostic criteria, and treatment options for managing constipation and DIOS in PwCF.
The invention relates to a method of delivering an olfactory composition, the method comprising the following steps: A1. retrieving at least one index of the physiological and/or emotional state of at least one user; A2. determining a physiological and/or emotional state from the index of the physiological and/or emotional state of said user; A3. determining at least one olfactory composition based at least in part on the determined physiological and/or emotional state of the user, A4. issuing said at least one determined olfactory composition. The invention also relates to a system for delivering such a suitable olfactory composition.
Participants will receive a 1-day loading dose of GS-1720/GS-4182 FDC on Day 1. Thereafter, participants will receive GS-1720/GS-4182 FDC tablets weekly + PTM B/F/TAF once daily. Participants will receive treatment for at least 96 weeks.
BACKGROUND: The causes of functional constipation (FC) in adults are unclear, but changes in the gut microbiome may play an important role. The present study aimed to assess the relationship between urinary metabolites of dopamine and serotonin and some dysbiosis indicators in patients with FC. The study included 40 healthy women and 40 women with FC aged 21-46 years.
METHODS: Urinary levels of homovanillic acid (HVA), 5-hydoxyindoleacetic acid (5-HIAA), p-hydroxyphenylacetic acid (PhAc), and 3-indoxyl sulfate, as final metabolites of dopamine, serotonin, and indole pathway, respectively, were determined using the LC-Ms/Ms method. However, hydrogen-methane and ammonia breath tests were performed. The GA-map Dysbiosis Test was used to identify and characterize the dysbiosis index (DI).
RESULTS: In patients with FC, the DI was significantly higher than in the control group: 4.05 ± 0.53 vs. 1.52 ± 0.81 points (p < 0.001), but the number of many types of bacteria varied among individuals. The levels of HVA were higher, while 5-HIAA levels were lower in patients. Moreover, the HVA/5-HIAA ratio had a positive correlation with DI as well as with the severity of symptoms.
CONCLUSIONS: In patients with functional constipation, the balance in dopamine and serotonin secretion is disturbed, which is associated with changes in the gut microbiome.
PURPOSE: Provided is a polymer supporter prepared by adding a drug in the process for preparing a polymer supporter using a biodegradable polyester-based polymer and an effervescent salt. Therefore, a drug included in the supporter is slowly released for an extended period in the case when the polymer supporter is implanted into a human body and can be widely used in drug therapy for a long period of time. CONSTITUTION: A biodegradable polyester-based polymer having a molecular weight of 5,000 to 500,000 Da and an desired drug are dissolved in an organic solvent and added with a concentrated solvent to produce a concentrated polymer solution. Thereafter, an effervescent salt is added to the polymer solution and the organic solvent is removed from the obtained gel to produce dried gel slurry. The dried gel slurry is steeped in an acidic aqueous solution and washed. The drug is dexamethasone, hydrocortisone, betamethasone, cortisone acetate or a mixture.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other asparaginase products may be misleading.

In Study CCG-1962, ONCASPAR treated patients were assessed for evidence of binding antibodies using an enzyme-linked immunosorbent assay (ELISA) method. The incidence of protocol-specified "high-titer" antibody formation was 2% in Induction (n=48), 10% in Delayed Intensification 1 (n=50), and 11% in Delayed Intensification 2 (n=44). In study CCG-1962, there is insufficient information to determine whether the development of antibodies is associated with an increased risk of clinical allergic reactions or altered pharmacokinetics (i.e., loss of asparaginase activity).

In Study DFCI 11-001, of the 100 evaluable patients treated with ONCASPAR, 19 (19%) patients developed anti-drug antibodies (ADA) during treatment; 18 of these 19 patients were positive for anti-PEG antibodies. The presence of ADA correlated with the occurrence of hypersensitivity reactions. There is insufficient information to determine whether the development of antibodies is associated with altered pharmacokinetics (i.e., loss of asparaginase activity).
Here we describe the production of commercial filtered standardized cannabidiol (CBD) hemp / tobacco blend cigarettes (HTC). This blended cigarette is designed to aid in smoking cessation.  Research has suggested that inhaling CBD cigarettes can significantly reduce a smoker's cravings for nicotine. Along with the CBD in the cigarettes, tobacco will be added to the cigarettes. 4 different strengths of cigarettes will be made. The amount of CBD at every cigarette strength will be 20% however the level of tobacco will vary. The highest cigarette strengths will have the largest amount of tobacco and the last level having zero tobacco. The smoker will start at a higher tobacco level, slowing going down to the lowest level at 6 week intervals or at their pace and discretion. At the lowest strength the smoker will have ceased smoking tobacco. At all strength levels of cigarettes they will have a very low amount (less than .3% per cigarette) of tetrahydrocannabinol (THC) (THC is the principal cannabinoid in cannabis that causes psychoactive effects).